Streetbeat News

Revenues

OSA

ProSomnus, Inc. (NASDAQ:OSA) announced successful treatment of Obstructive Sleep Apnea (OSA) with its precision oral appliance therapy devices, as published in the Cureus Journal of Medical Science. The study showed high treatment success rates, strong patient compliance, and better outcomes compared to other treatments. The company highlighted additional research demonstrating the efficacy and adherence of its devices in multiple clinical settings, positioning its products as a credible alternative to CPAP therapy.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 1:08 pm

BFLY

Butterfly Network, Inc. (BFLY) has entered into a commercial agreement with Mendaera to integrate Butterfly's Ultrasound-on-Chip technology into Mendaera's next-generation robotic system for interventional procedures. The partnership is expected to generate revenue for Butterfly from each unit sold post-commercialization. The product, which aims to improve precision in image-guided interventions, is anticipated to be submitted to the FDA by 2025. This follows Mendaera's $24 million Series A funding round and the completion of their research and design process.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 1:07 pm

BYRN

Byrna Technologies reported preliminary Q4 2023 revenue of $15.6 million, surpassing the estimate of $11.36 million.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 1:03 pm

WOOF

Analysts have provided various ratings for Petco Health and Wellness (NASDAQ:WOOF) over the past quarter, with an average price target of $3.94, down from the previous $6.25. The ratings include 2 bullish, 3 somewhat bullish, and 2 indifferent. Notably, analysts from Jefferies, Morgan Stanley, RBC Capital, Goldman Sachs, Wedbush, and Needham have lowered their price targets. Petco's financial performance shows challenges with negative revenue trends, low net margin, ROE, and ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 1:00 pm

CRNX

Crinetics Pharmaceuticals (NASDAQ:CRNX) received 4 analyst ratings in the last quarter, with an average 12-month price target of $44.25, down from the previous $52.00. Ratings include 1 bullish and 3 overweight, with price targets ranging from $35.00 to $50.00. The company's financial health shows challenges with a revenue decline of -24.45%, a net margin of -16606.36%, and ROE of -14.33%. Despite this, it maintains a low debt-to-equity ratio of 0.1.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 1:00 pm

ARVN

Arvinas Inc (NASDAQ:ARVN) has been analyzed by 9 analysts in the last quarter, with 4 bullish, 4 somewhat bullish, and 1 indifferent rating. The average 12-month price target is $38.44, down 15.39% from the previous $45.43. Analysts from firms like Wells Fargo, Jefferies, and Morgan Stanley have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Arvinas's financials show a revenue growth rate of 4.22% as of September 30, 2023, but lag behind industry peers. The company has a net margin of -184.97%, an ROE of -13.9%, an ROA of -5.98%, and a low debt-to-equity ratio of 0.01.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 1:00 pm

ENPH

Enphase Energy Inc (NASDAQ:ENPH) is reducing its global workforce by 10%, ceasing operations in Romania and Wisconsin, and resizing other manufacturing sites. The company will focus on U.S. production, aiming for a capacity of 7.25 million microinverter units per quarter. The restructuring will cost $16-$18 million, with $7 million in cash expenditures. Enphase anticipates non-GAAP operating expenses of $75-$80 million per quarter by 2024. The decision follows reduced demand for solar inverters in the U.S. due to metering reform and higher lending rates. ENPH shares rose 1.27% in premarket trading.

Portfolio Pulse from Shivani Kumaresan

December 19, 2023 | 12:43 pm

AZN

CGEN

Compugen announced it will receive a $10M milestone payment once the first patient is dosed in AstraZeneca's Phase 3 trial of Rilvegostomig for biliary tract cancer.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 12:12 pm

BCRX

BioCryst Pharmaceuticals announced that data from the open-label extension of the APEX-2 trial of Orladeyo for prophylactic treatment of hereditary angioedema in patients aged 12 and older has been published by the Journal of Allergy & Clinical Immunology: In Practice.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 12:11 pm

CGEN

GILD

Gilead Sciences has entered into an exclusive license agreement with Compugen for a pre-clinical immunotherapy program, potentially worth up to $848 million. Gilead will pay Compugen $60 million upfront, $30 million upon IND clearance of COM503, and up to $758 million in additional milestone payments. Compugen is also set to receive royalties on worldwide net sales.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 12:04 pm